Keywords: biogen, claims, avonex, ahead, betaferon, torsten, goesch

Biogen claims Avonex ahead of Betaferon

Article | 22 July 1999

Print This

Torsten Goesch, managing director of Biogen's German unit hasclaimed that sales of its multiple sclerosis therapy Avonex (interferon beta-1a) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in